Augmented anticancer efficacy of doxorubicin-loaded polymeric nanoparticles after oral administration in a breast cancer induced animal model.

The present investigation reports an extensive evaluation of in vitro and in vivo anticancer efficacy of orally administered doxorubicin-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (Dox-NPs) in a breast cancer induced animal model. Spherically shaped Dox-NPs were prepared with an entrapment efficiency and particle size of 55.40 ± 2.30% and 160.20 ± 0.99 nm, respectively, and freeze-dried with 5% trehalose using stepwise freeze-drying. Cytotoxicity, as investigated on C127I cell line, revealed insignificant differences between the IC(50) of free Dox and Dox-NPs treated cells in the first 24 h, while higher cytotoxicity was demonstrated by Dox-NPs, following 72 h of incubation. Confocal laser scanning microscopy (CLSM) imaging corroborated that nanoparticles were efficiently localized into the nuclear region of C127I cells. The cellular uptake profile of Dox-NPs revealed both time and concentration dependent increases in the Caco-2 cell uptake as compared to the free Dox solution. Further, Dox-NPs significantly suppressed the growth of breast tumor in female Sprague-Dawley (SD) rats upon oral administration. Finally, orally administered Dox-NPs showed a marked reduction in cardiotoxicity when compared with intravenously injected free Dox as also evident by the increased level of malondialdehyde (MDA), lactate dehydrogenase (LDH), and creatine phosphokinase (CK-MB) and reduced levels of glutathione (GSH) and superoxide dismutase (SOD). The reduced cardiotoxicity of orally administered Dox-NPs was also confirmed by the major histopathological changes in the heart tissue after the treatments of intravenously injected free Dox and orally delivered Dox-NPs.

[1]  Amit Jain,et al.  Cyclosporin A Loaded PLGA Nanoparticle: Preparation, Optimization, In-Vitro Characterization and Stability Studies , 2010 .

[2]  Amit Jain,et al.  The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly(gamma-benzyl L-glutamate)-b-hyaluronan polymersomes. , 2010, Biomaterials.

[3]  Yi Ding,et al.  Synthesis, characterization, and in vitro and in vivo evaluation of a novel pectin-adriamycin conjugate. , 2010, Bioorganic & medicinal chemistry.

[4]  C. Lehr,et al.  PLGA Nanoparticles Stabilized with Cationic Surfactant: Safety Studies and Application in Oral Delivery of Paclitaxel to Treat Chemical-Induced Breast Cancer in Rat , 2009, Pharmaceutical Research.

[5]  A. Maitra,et al.  Dextran-doxorubicin/chitosan nanoparticles for solid tumor therapy. , 2009, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[6]  Russell J Mumper,et al.  Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. , 2009, Cancer research.

[7]  G. Sharma,et al.  Design of Biodegradable Nanoparticles for Oral Delivery of Doxorubicin: In vivo Pharmacokinetics and Toxicity Studies in Rats , 2009, Pharmaceutical Research.

[8]  Rongqin Huang,et al.  Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system. , 2008, Journal of pharmaceutical sciences.

[9]  Pushpa Mishra,et al.  Preparation and characterization of HA–PEG–PCL intelligent core–corona nanoparticles for delivery of doxorubicin , 2008 .

[10]  Pushpa Mishra,et al.  Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. , 2007, Nanomedicine : nanotechnology, biology, and medicine.

[11]  H. Wong,et al.  Doxorubicin-induced cardiotoxicity: direct correlation of cardiac fibroblast and H9c2 cell survival and aconitase activity with heat shock protein 27. , 2007, American journal of physiology. Heart and circulatory physiology.

[12]  Lisa Brannon-Peppas,et al.  Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. , 2007, Nanomedicine.

[13]  S. Stainmesse,et al.  Freeze-drying of nanoparticles: formulation, process and storage considerations. , 2006, Advanced drug delivery reviews.

[14]  X. Wu,et al.  A Mechanistic Study of Enhanced Doxorubicin Uptake and Retention in Multidrug Resistant Breast Cancer Cells Using a Polymer-Lipid Hybrid Nanoparticle System , 2006, Journal of Pharmacology and Experimental Therapeutics.

[15]  C. Astete,et al.  Synthesis and characterization of PLGA nanoparticles , 2006, Journal of biomaterials science. Polymer edition.

[16]  Si-Shen Feng,et al.  Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. , 2005, Biomaterials.

[17]  Si-Shen Feng,et al.  Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. , 2005, Biomaterials.

[18]  R. Murthy,et al.  Pharmacokinetics and biodistribution studies of Doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles synthesized by two different techniques. , 2004, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[19]  Vinod Nair,et al.  Biopharmaceutic classification system: a scientific framework for pharmacokinetic optimization in drug research. , 2004, Current drug metabolism.

[20]  M. Fahr,et al.  Effect of glutamine on the initiation and promotion phases of DMBA-induced mammary tumor development. , 2003, JPEN. Journal of parenteral and enteral nutrition.

[21]  K. Fukuzawa,et al.  High cytotoxicity of alpha-tocopheryl hemisuccinate to cancer cells is due to failure of their antioxidative defense systems. , 2002, Cancer letters.

[22]  J. Quiles,et al.  Antioxidant nutrients and adriamycin toxicity. , 2002, Toxicology.

[23]  C. Vogel,et al.  Pegylated Liposomal Doxorubicin (Doxil®) for Metastatic Breast Cancer: The Cancer Research Network, Inc., Experience , 2002, Cancer investigation.

[24]  N Hussain,et al.  Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. , 2001, Advanced drug delivery reviews.

[25]  B. Hirst,et al.  Exploiting M cells for drug and vaccine delivery. , 2001, Advanced drug delivery reviews.

[26]  A. Maitra,et al.  Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[27]  K. Janes,et al.  Chitosan nanoparticles as delivery systems for doxorubicin. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[28]  E. Voest,et al.  Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review. , 2001, European journal of pharmacology.

[29]  J. Schellens,et al.  Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  S. Davis,et al.  PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[31]  P. Singal,et al.  Doxorubicin-induced cardiomyopathy. , 1998, The New England journal of medicine.

[32]  Alexander T. Florence,et al.  The Oral Absorption of Micro- and Nanoparticulates: Neither Exceptional Nor Unusual , 1997, Pharmaceutical Research.

[33]  M. Moore,et al.  Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumor cells. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  キングストン，アン・イー,et al.  Method of treating multiple sclerosis , 1996 .

[35]  P. Couvreur,et al.  Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles , 1992, Investigational New Drugs.

[36]  H. Maeda.  The tumor blood vessel as an ideal target for macromolecular anticancer agents , 1992 .

[37]  B. Hankey,et al.  Second cancers following non‐Hodgkin's lymphoma , 1991, Cancer.

[38]  R. Olson,et al.  Doxorubicin cardiotoxicity: analysis of prevailing hypotheses , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  R. Conradi,et al.  Caco-2 Cell Monolayers as a Model for Drug Transport Across the Intestinal Mucosa , 1990, Pharmaceutical Research.

[40]  P. Artursson,et al.  Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. , 1990, Journal of pharmaceutical sciences.

[41]  S. Rehm.  Chemically induced mammary gland adenomyoepitheliomas and myoepithelial carcinomas of mice. Immunohistochemical and ultrastructural features. , 1990, The American journal of pathology.

[42]  R. Olson,et al.  Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[44]  L. Mawdesley-Thomas.  Research into Fish Diseases , 1972, Nature.

[45]  W. Pigram,et al.  Stereochemistry of intercalation: interaction of daunomycin with DNA. , 1972, Nature: New biology.

[46]  Amit Jain,et al.  The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. , 2011, Biomaterials.

[47]  T. K. Yeung,et al.  Reduced cardiotoxicity of doxorubicin given in the form ofN-(2-hydroxypropyl) methacrylamide conjugates: an experimental study in the rat , 2004, Cancer Chemotherapy and Pharmacology.

[48]  Yechezkel Barenholz,et al.  Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.

[49]  J. Quiles,et al.  Coenzyme Q content depends upon oxidative stress and dietary fat unsaturation. , 1997, Molecular aspects of medicine.

[50]  W T Bellamy,et al.  P-glycoproteins and multidrug resistance. , 1996, Annual review of pharmacology and toxicology.

[51]  F. Baas,et al.  Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. , 1993, Pharmacology & therapeutics.

[52]  U. Das,et al.  Increase in free radical generation and lipid peroxidation following chemotherapy in patients with cancer. , 1990, Free radical biology & medicine.

[53]  I. Pastan,et al.  Expression of a multidrug-resistance gene in human tumors and tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.